We also observed increased expression of the activation/effector markers CD25, NKG2D, CX3CR1 and CD39 on the surface of CD8+ T cells in tumor, spleen, and blood following treatment with IL-2/JES6 alone or after ICIs (online supplemental figure 5D-J). This evidence concerns the gene CD8A and neoplasm.